Analysis of antibacterial and antibiofilm activity of purified recombinant Azurin from
Antibacterial effect
Antibiofilm activity
Recombinant Azurin
Journal
Iranian journal of microbiology
ISSN: 2008-3289
Titre abrégé: Iran J Microbiol
Pays: Iran
ID NLM: 101518404
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
entrez:
26
7
2019
pubmed:
26
7
2019
medline:
26
7
2019
Statut:
ppublish
Résumé
The aim of this study was to evaluate the antibacterial and antibiofilm activity of recombinant Azurin from The The identity of purified protein was confirmed by blotting and distinguished as a 14 kDa band on 15% SDS-PAGE. The IC50 of rAzurin on Peripheral Blood Mononuclear Cell (PBMC) was determined as 377.91±0.5 μg/mL in 24 h. The rAzurin appears to be an appropriate choice and a new strategy for prevention of bacterial infection. It inhibits bacterial growth and biofilm formation and candidates as antimicrobial peptides.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
The aim of this study was to evaluate the antibacterial and antibiofilm activity of recombinant Azurin from
MATERIALS AND METHODS
METHODS
The
RESULTS
RESULTS
The identity of purified protein was confirmed by blotting and distinguished as a 14 kDa band on 15% SDS-PAGE. The IC50 of rAzurin on Peripheral Blood Mononuclear Cell (PBMC) was determined as 377.91±0.5 μg/mL in 24 h.
CONCLUSION
CONCLUSIONS
The rAzurin appears to be an appropriate choice and a new strategy for prevention of bacterial infection. It inhibits bacterial growth and biofilm formation and candidates as antimicrobial peptides.
Types de publication
Journal Article
Langues
eng
Pagination
166-176Références
Antonie Van Leeuwenhoek. 1999 Jul-Nov;76(1-4):279-92
pubmed: 10532384
Gut. 2000 Jul;47(1):79-87
pubmed: 10861268
Emerg Infect Dis. 2002 Sep;8(9):881-90
pubmed: 12194761
Microbiol Rev. 1992 Sep;56(3):395-411
pubmed: 1406489
Oncogene. 2004 Mar 25;23(13):2367-78
pubmed: 14981543
Curr Pharm Des. 2004;10(19):2299-310
pubmed: 15279610
Cancer Res. 2005 Jun 1;65(11):4645-52
pubmed: 15930282
J Ethnopharmacol. 2005 Aug 22;100(1-2):80-4
pubmed: 15964727
Cell Microbiol. 2005 Oct;7(10):1418-31
pubmed: 16153242
Infect Immun. 2005 Dec;73(12):8444-8
pubmed: 16299348
Cell Cycle. 2006 Aug;5(15):1642-8
pubmed: 16861897
Chem Biol. 2007 Oct;14(10):1119-27
pubmed: 17961824
Antimicrob Agents Chemother. 2008 Feb;52(2):402-8
pubmed: 18070964
Nat Protoc. 2008;3(2):163-75
pubmed: 18274517
PLoS Pathog. 2008 Apr 25;4(4):e1000052
pubmed: 18437240
Int J Antimicrob Agents. 2008 Nov;32 Suppl 1:S2-9
pubmed: 18757182
Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19456-61
pubmed: 19047636
J Bacteriol. 2009 Mar;191(5):1393-403
pubmed: 19074399
J Med Microbiol. 2010 May;59(Pt 5):573-9
pubmed: 20110387
Microbiology. 2010 Sep;156(Pt 9):2587-96
pubmed: 20616105
Protein Cell. 2010 Feb;1(2):143-52
pubmed: 21203984
Indian J Pharmacol. 2008 Jan;40(1):3-9
pubmed: 21264153
FEBS Lett. 1990 Feb 12;261(1):196-8
pubmed: 2155133
Clin Orthop Relat Res. 2012 Oct;470(10):2663-70
pubmed: 22585351
Curr Med Chem. 2012;19(36):6188-98
pubmed: 22978329
PLoS One. 2013;8(2):e56081
pubmed: 23409125
Pathog Dis. 2014 Apr;70(3):231-9
pubmed: 24453168
Eur J Biochem. 1989 Jan 15;179(1):195-200
pubmed: 2537198
FEBS Lett. 1989 Mar 27;246(1-2):211-7
pubmed: 2540038
Pathogens. 2014 Jun 18;3(2):473-98
pubmed: 25437810
Biomed Res Int. 2015;2015:453826
pubmed: 25815317
Future Med Chem. 2015;7(5):647-71
pubmed: 25921403
Curr Top Med Chem. 2016;16(1):76-88
pubmed: 26139115
J Bacteriol. 2016 Sep 09;198(19):2572-8
pubmed: 27068589
Microbiol Res. 2016 Jul-Aug;188-189:34-41
pubmed: 27296960
BMC Microbiol. 2016 Sep 21;16(1):220
pubmed: 27654924
Evid Based Complement Alternat Med. 2017;2017:5163575
pubmed: 28127379
Virulence. 2018 Jan 1;9(1):522-554
pubmed: 28362216